Vraylar — Net revenues
Products & Services · Net revenuesAbbVie Vraylar — Net revenues increased by 9.4% to $1.02B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.6%, from $924.00M to $1.02B. Over 4 years (FY 2021 to FY 2025), Vraylar — Net revenues shows an upward trend with a 20.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market demand, successful physician adoption, or effective commercial execution, while a decrease may signal increased competition, patent expiration, or loss of market share.
Detailed definition
This metric represents the total gross sales of the specific pharmaceutical product line, adjusted for returns, allowanc...
Peer comparison
Comparable to net product sales reported by other pharmaceutical companies for specific branded drugs or therapeutic franchises.
abbv_segment_vraylar_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $432.00M | $432.00M | $432.00M | $427.00M | $492.00M | $554.00M | $565.00M | $561.00M | $658.00M | $751.00M | $789.00M | $694.00M | $774.00M | $875.00M | $924.00M | $765.00M | $900.00M | $934.00M | $1.02B |
| QoQ Change | — | +0.0% | +0.0% | -1.2% | +15.2% | +12.6% | +2.0% | -0.7% | +17.3% | +14.1% | +5.1% | -12.0% | +11.5% | +13.0% | +5.6% | -17.2% | +17.6% | +3.8% | +9.4% |
| YoY Change | — | — | — | — | +13.9% | +28.2% | +30.8% | +31.4% | +33.7% | +35.6% | +39.6% | +23.7% | +17.6% | +16.5% | +17.1% | +10.2% | +16.3% | +6.7% | +10.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's vraylar — net revenues?
- AbbVie (ABBV) reported vraylar — net revenues of $1.02B in Q4 2025.
- How has AbbVie's vraylar — net revenues changed year-over-year?
- AbbVie's vraylar — net revenues increased by 10.6% year-over-year, from $924.00M to $1.02B.
- What is the long-term trend for AbbVie's vraylar — net revenues?
- Over 4 years (2021 to 2025), AbbVie's vraylar — net revenues has grown at a 20.3% compound annual growth rate (CAGR), from $1.73B to $3.62B.
- What does vraylar — net revenues mean?
- The total net sales generated by the specific pharmaceutical product after accounting for discounts and returns.